Ferric Carboxymaltose in Heart Failure with Iron Deficiency
Source: View publication →
In the HEART-FID trial, intravenous ferric carboxymaltose did not significantly improve a hierarchical composite outcome of death, heart failure hospitalization, and 6-minute walk distance in ambulatory patients with heart failure with reduced ejection fraction and iron deficiency.
Key Findings
Study Design
Study Limitations
Clinical Significance
While HEART-FID was neutral, the totality of evidence from previous trials (e.g., CONFIRM-HF, AFFIRM-AHF) and the modest numerical improvements observed across all components of the primary endpoint in HEART-FID continue to support the safety and potential clinical benefit of intravenous iron in appropriate patients with HFrEF and iron deficiency. The findings underscore the importance of patient selection and the potential impact of baseline iron status (TSAT) on treatment efficacy.
Historical Context
Prior trials such as FAIR-HF and CONFIRM-HF established that intravenous ferric carboxymaltose improves functional capacity and quality of life in HFrEF patients with iron deficiency. While subsequent trials like AFFIRM-AHF and IRONMAN suggested benefits regarding hospitalizations, they were also impacted by the COVID-19 pandemic. HEART-FID was the largest trial to date, designed to provide definitive evidence on long-term safety and clinical outcomes; however, its neutral result—likely influenced by a lower-risk population and baseline iron characteristics—highlights the complexity of evaluating iron repletion in contemporary heart failure management.
Guided Discussion
High-yield insights from every perspective
Why is iron deficiency (ID) considered a therapeutic target in heart failure with reduced ejection fraction (HFrEF) even when the patient does not have clinical anemia (hemoglobin >12-13 g/dL)?
Key Response
Iron is a critical cofactor for mitochondrial enzymes and myoglobin. In HFrEF, iron deficiency impairs cellular energetics and oxygen utilization in both cardiac and skeletal muscle. Clinical trials show that repletion can improve functional capacity and quality of life independent of its effects on erythropoiesis.
According to the HEART-FID trial criteria, which specific laboratory thresholds define iron deficiency in patients with heart failure, and how does this differ from the definition used for the general population?
Key Response
HEART-FID defined iron deficiency as a ferritin level <100 xg/L or 100-299 xg/L with a transferrin saturation (TSAT) <20%. This is much broader than the general population threshold (ferritin <30 xg/L), reflecting the chronic inflammatory state of heart failure where 'functional' iron deficiency occurs despite seemingly normal stores.
The HEART-FID trial used a hierarchical composite primary endpoint analyzed via the Win Ratio. How does this statistical approach influence the interpretation of the results compared to a traditional time-to-first-event analysis?
Key Response
The Win Ratio prioritizes more severe events (Death > HF Hospitalization > 6-minute walk distance). While it prevents a common event (like a change in 6-MWD) from dominating a rare but critical one (death), the non-significant result (Win Ratio 1.10) suggests that even with this prioritization, the treatment effect was not robust enough across the tiered outcomes to achieve statistical significance.
Given that HEART-FID did not meet its primary endpoint, how should this trial change your clinical approach to stable ambulatory HFrEF patients compared to the post-acute discharge population studied in AFFIRM-AHF?
Key Response
HEART-FID suggests that the benefit of IV Ferric Carboxymaltose (FCM) may be more modest in stable outpatients than previously hoped. However, because the trial trended toward benefit and showed no safety concerns, most experts still recommend screening and treating based on the totality of evidence (meta-analyses) which still point toward a reduction in HF hospitalizations, particularly in those recently hospitalized.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
How might the inclusion of the 6-minute walk distance (6-MWD) as the third tier in the hierarchical composite endpoint have affected the study's power, specifically considering the impact of the COVID-19 pandemic on data collection?
Key Response
Functional endpoints like 6-MWD are prone to high variance and missing data. The pandemic disrupted many in-person assessments, potentially introducing 'noise' into the lower tier of the Win Ratio analysis. This increased variability in the 6-MWD component could have diluted the treatment effect seen in the more objective tiers (mortality and hospitalizations), contributing to the p=0.019 result (which missed the prespecified alpha of 0.01).
As a reviewer, how would you evaluate the decision to set the significance threshold at p<0.01 for HEART-FID, and what does this imply about the trial's 'negative' conclusion?
Key Response
The stricter alpha (0.01) was chosen due to interim analyses. With a p-value of 0.019, the trial is technically 'negative' by its own pre-specified rules, yet in many other contexts, this would be considered statistically significant. A reviewer would flag this as a 'borderline' result that requires a nuanced discussion of clinical vs. statistical significance rather than a binary interpretation.
The 2022 AHA/ACC/HFSA guidelines give IV iron a Class 2a recommendation for HFrEF and iron deficiency. Does HEART-FID provide sufficient evidence to either upgrade this to Class 1 or necessitate a downgrade due to its failed primary endpoint?
Key Response
A downgrade is unlikely because HEART-FID confirmed the safety of FCM and trended toward benefit, aligning with the direction of FAIR-HF and CONFIRM-HF. However, an upgrade to Class 1 for mortality or hospitalization reduction is now less likely, as the largest trial to date failed to reach its primary objective. The recommendation will likely remain focused on functional improvement and symptom management (Class 2a/I) while highlighting the uncertainty in mortality benefit.
Clinical Landscape
Noteworthy Related Trials
CONFIRM-HF Trial
Tested
Ferric carboxymaltose
Population
Symptomatic heart failure patients with iron deficiency
Comparator
Placebo
Endpoint
Change in 6-minute walk distance
AFFIRM-AHF Trial
Tested
Ferric carboxymaltose
Population
Patients hospitalized for acute heart failure with iron deficiency
Comparator
Placebo
Endpoint
Total hospitalizations for heart failure and cardiovascular death
IRONMAN Trial
Tested
Ferric derisomaltose
Population
Heart failure patients with reduced ejection fraction and iron deficiency
Comparator
Usual care
Endpoint
Recurrent hospitalizations for heart failure and cardiovascular death
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis